Business Wire

NILIT

26.8.2024 21:03:49 CEST | Business Wire | Press release

Share
Samsara Eco and NILIT Team up to Build World-First Nylon 6,6 Recycling Facility

Samsara Eco, the enviro-tech innovator and NILIT, the world’s leader in the production of nylon 6,6 for apparel, have announced plans to explore investment and construction of a nylon 6,6 textile-to-textile recycled polymer production site in South East Asia to help close the loop on nylon 6,6.

Roughly 4 million tonnes of nylon 6,6 is created every year, it is one of the most widely used fibers in the performance apparel and fashion industries. However, it is notoriously difficult to recycle and when blended with other fibres like spandex, it increases the challenge. Together, Samsara Eco and NILIT are seeking to address this issue head-on.

Aiming to be operational by late 2026, the anticipated facility will be uniquely capable of recycling textile waste, producing high-quality recycled nylon 6,6 polymers, for textile brands and manufacturers to seamlessly use in their existing supply chains to create new textile fabrics, infinitely.

“Our vision is to deliver climate repair through infinite recycling. One of the ways we’re achieving this is by creating the first circular pathway for nylon 6,6. Discarded clothing made from nylon 6,6 such as activewear, and even products like car interiors, typically end up in landfill or are incinerated at the end of life, which has dire consequences for our planet,” said Paul Riley, CEO and Founder of Samsara Eco.

Sarah Cook, Chief Commercial and Operations Officer of Samsara Eco also commented on the agreement: “By working with NILIT, we can reverse this trend and give apparel a new life. The MoU agreement is an important step to help brands and the world advance nylon 6,6 circularity and reduce plastic waste. We’re proud to be exploring a pilot recycling facility with NILIT, setting a precedent of what’s possible for future partners globally.”

“NILIT’s partnership with Samsara Eco is a critical step in our multi-pronged strategy to provide the apparel market with premium nylon 6,6 products that have lower environmental impact,” explained Ilan Melamed, NILIT General Manager. “Implementing textile-to-textile recycling solutions will substantially decrease global carbon emissions and reduce the 92 million tonnes of textile waste added to landfills annually. Together, NILIT and Samsara Eco have the potential to produce infinitely recycled nylon 6,6 that delivers outstanding fabric quality and performance while benefitting the planet.”

EosEco™ is the world's first technology to infinitely recycle nylon 6,6 by combining biophysics, chemistry, biology and computer science (such as AI) to create a family of plastic-eating enzymes. The enzymes break down plastic waste, including textiles made from nylon 6,6 into raw materials, which are then seamlessly integrated into existing manufacturing processes to create a truly closed loop. EosEco™ can recycle a breadth of feedstock inputs, including coloured and blended textiles like nylon 6,6 with spandex. EosEco™, together with NILIT’s unique polymerization, spinning and technology will be able to create premium recycled Nylon 6, 6 yarn for global consumption.

About NILIT

Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6,6 yarns designed to empower the apparel industry’s shift to a more sustainable position. Operating internationally, NILIT is the global leader in Nylon 6,6 yarns for apparel, dedicated to creating innovative and sustainable solutions that advance the textile industry.

NILIT will add Samsara Eco’s EosEco™ produced yarn to its innovative SENSIL® preferred portfolio of products which is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.

About Samsara Eco

Samsara Eco is using advanced, enzymatic recycling to end plastic pollution. With breakthrough science, Samsara Eco has developed a new way to break plastic down to its core molecules, which can then be used to recreate brand-new plastic, again and again. Its patented technology, EosEco™ is a first-of-its-kind process that is genuinely better for the planet.

Samsara Eco’s community is united by the shared mission to divert plastic from our landfills and oceans, and eliminate the need to create plastic from fossil fuels, (whether it’s for the bottles we drink from or the clothes we wear) for a cleaner and more sustainable future.

In partnership with the Australian National University (ANU), Samsara Eco launched in 2020 with the backing of Main Sequence and Woolworths Group’s W23. It has raised more than AUD $160M in funding from local and global investors including Breakthrough Victoria, DCVC, Hitachi, lululemon, Temasek, Wildcard Ventures, Wollemi Capital and more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820332060/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye